Pablo Corral on Lipid-Lowering Therapy and Cognition: Evidence vs Myth
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Lipid-Lowering Therapy and Cognition: Evidence vs Myth
1. Elevated LDL-C remains the leading modifiable risk factor for cardiovascular disease and a major contributor to global mortality.
2. Concerns about cognitive adverse effects of lipid-lowering therapies (LLTs), particularly statins, are largely driven by early case reports rather than robust clinical evidence.
3. Observational studies and randomized trials consistently show no significant association between statin use and cognitive decline, with some data suggesting potential protective effects against dementia.
4. Major randomized trials (HPS, PROSPER, HOPE-3) found no difference in cognitive outcomes between statin-treated and placebo groups.
5. PCSK9 inhibitors (evolocumab, alirocumab) demonstrate neurocognitive safety, even with very low LDL-C levels and long-term exposure.
6. Ezetimibe and bempedoic acid show neutral neurocognitive profiles, with emerging signals of possible neuroprotective effects.
Current data support a clear conclusion:
- Lowering LDL-C improves cardiovascular outcomes without meaningful cognitive harm.
- The real knowledge gap is not safety, but understanding whether lipid-lowering therapies might also confer long-term neuroprotection.
Take-home message:
Fear of cognitive decline should not justify therapeutic inertia.
The price of untreated LDL-C is cardiovascular disease—not cognitive impairment.”
Read the full article here.
Article: Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations
Authors: Raiza Rossi, Armin Nouri, Zafer Akman, Shefa Arya Nezhad, Abdulla A. Damluji, Michael G. Nanna
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers